Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
about
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancerEvaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis.Is anti-hormonal treatment in DCIS of the breast a need?Breast Cancer Profile among Patients with a History of Chemoprevention.Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials.Cancer Prevention: Lessons Learned and Future Directions.Current approach and future perspective for ductal carcinoma in situ of the breast.Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes.Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes.Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast.Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.Controversies in the Treatment of Ductal Carcinoma in Situ.Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.
P2860
Q36348871-A660B533-2522-4F5B-946B-1A5DD47F3AF9Q36370970-8E782910-EF52-4494-B97F-7FBC6D4179E7Q37519958-2DB6F05B-20CE-4474-A0AE-04158F776522Q37547625-92DE3502-79DF-49A3-8BA3-CA1BBB100355Q38611952-DBBB4BA4-C8D0-435D-8BDF-F13AACF25C33Q38652183-C45FBE34-37DC-438A-97A4-85D4E52584D0Q38685947-65A1B9FF-E2DF-411E-8D2E-9AF5291B7170Q38805888-87C39468-9183-4507-9B7B-0B1277264AABQ38837580-4616642B-5E95-4396-92F8-265CAB97D513Q38882550-7F7666B6-03B2-4A69-8458-8263EA1D1193Q40498040-2A081950-B6E7-40BA-A9BC-E4BDDBFE7927Q40665794-4965D440-F36D-4217-91B3-F59E21792CFFQ41721847-85FB4842-1990-4241-AAC0-A30785BC0B27Q43375008-9515D014-687E-4B2F-BB1E-6BA0B65C204AQ47097148-0CDBD1C1-B9B0-4410-91E5-0EE81F90BD05Q48558036-B0854F1E-A0F3-47AC-A34B-23FDD22FE82EQ49657306-B7CF1E82-62E6-482E-AA0C-F2895E53D023Q55515741-F2A54F04-B2EF-4A69-B69B-BC02429E1E7B
P2860
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@ast
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@en
type
label
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@ast
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@en
prefLabel
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@ast
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@en
P2093
P2860
P50
P1433
P1476
Anastrozole versus tamoxifen f ...... d, randomised controlled trial
@en
P2093
Bernardo Bonanni
Chris Holcombe
Christelle Levy
IBIS-II investigators
Ivana Sestak
Jack Cuzick
John F Forbes
Louise Jones
Michael Stierer
Nigel Bundred
P2860
P304
P356
10.1016/S0140-6736(15)01129-0
P407
P577
2015-12-11T00:00:00Z